Top

Published in:

01-07-2018 | Review Article

Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer

A systematic review

Authors: David Krug, René Baumann, Wilfried Budach, Jürgen Dunst, Petra Feyer, Rainer Fietkau, Wulf Haase, Wolfgang Harms, Thomas Hehr, Marc D. Piroth, Felix Sedlmayer, Rainer Souchon, Frederik Wenz, Rolf Sauer

Published in: Strahlentherapie und Onkologie | Issue 7/2018

Abstract

Purpose

To review the evidence regarding post-mastectomy radiotherapy (PMRT) and regional nodal irradiation (RNI) after neoadjuvant chemotherapy (NACT) for breast cancer, with a special focus on individualization of adjuvant radiotherapy based on treatment response.

Methods

A systematic literature search using the PubMed/Medline database was performed. We included prospective and retrospective reports with a minimum of 10 patients that had been published since 1^st January 2000, and provided clinical outcome data analyzed by treatment response and radiotherapy.

Results

Out of 763 articles identified via PubMed/Medline and hand search, 68 full text-articles were assessed for eligibility after screening of title and abstract. 13 studies were included in the systematic review, 9 for PMRT and 5 for RNI. All included studies were retrospective reports.

Conclusions

There is a considerable lack of evidence regarding the role of adjuvant radiotherapy and its individualization based on treatment response after NACT. Results of prospective randomized trials such as NSABP B‑51/RTOG 1304 and Alliance A11202 are eagerly awaited.

Kaufmann M, von Minckwitz G, Smith R et al (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21:2600–2608. https://doi.org/10.1200/JCO.2003.01.136 CrossRefPubMed

Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172. https://doi.org/10.1016/S0140-6736(13)62422-8 CrossRefPubMed

Mougalian SS, Soulos PR, Killelea BK et al (2015) Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer 121:2544–2552. https://doi.org/10.1002/cncr.29348 CrossRefPubMed

Hennigs A, Riedel F, Marmé F et al (2016) Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade. Breast Cancer Res Treat 160:491–499. https://doi.org/10.1007/s10549-016-4016-4 CrossRefPubMedPubMedCentral

Mamounas EP, Anderson SJ, Dignam JJ et al (2012) Predictors oflLocoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B‑18 and B‑27. J Clin Oncol 30:3960–3966. https://doi.org/10.1200/JCO.2011.40.8369 CrossRefPubMedPubMedCentral

Recht A, Comen EA, Fine RE et al (2016) Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update. J Clin Oncol 34:4431–4442. https://doi.org/10.1200/JCO.2016.69.1188 CrossRefPubMed

Sautter-Bihl ML, Sedlmayer F, Budach W et al (2014) DEGRO practical guidelines: radiotherapy of breast cancer III—radiotherapy of the lymphatic pathways. Strahlenther Onkol 190:342–351. https://doi.org/10.1007/s00066-013-0543-7 CrossRefPubMed

Wenz F, Sperk E, Budach W et al (2014) DEGRO practical guidelines for radiotherapy of breast cancer IV: radiotherapy following mastectomy for invasive breast cancer. Strahlenther Onkol 190:705–714. https://doi.org/10.1007/s00066-014-0687-0 CrossRefPubMed

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383:2127–2135. https://doi.org/10.1016/S0140-6736(14)60488-8 CrossRef

10.

Poortmans PM, Collette S, Kirkove C et al (2015) Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 373:317–327. https://doi.org/10.1056/NEJMoa1415369 CrossRefPubMed

11.

Whelan TJ, Olivotto IA, Parulekar WR et al (2015) Regional nodal irradiation in early-stage breast cancer. N Engl J Med 373:307–316. https://doi.org/10.1056/NEJMoa1415340 CrossRefPubMedPubMedCentral

12.

Burstein HJ, Morrow M (2015) Nodal irradiation after breast-cancer surgery in the era of effective adjuvant therapy. N Engl J Med 373:379–381. https://doi.org/10.1056/NEJMe1503608 CrossRefPubMed

13.

Marks LB, Kaidar-Person O, Poortmans P (2017) Regarding current recommendations for postmastectomy radiation therapy in patients with one to three positive axillary lymph nodes. J Clin Oncol 35:1256–1258. https://doi.org/10.1200/JCO.2016.71.0764 CrossRefPubMed

14.

Poortmans P (2014) Postmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate. Lancet 383:2104–2106. https://doi.org/10.1016/S0140-6736(14)60192-6 CrossRefPubMed

15.

Cassidy RJ, Liu Y, Kahn ST et al (2017) The role of postmastectomy radiotherapy in women with pathologic T3N0M0 breast cancer. Cancer 123:2829–2839. https://doi.org/10.1002/cncr.30675 CrossRefPubMed

16.

Floyd SR, Buchholz TA, Haffty BG et al (2006) Low local recurrence rate without postmastectomy radiation in node-negative breast cancer patients with tumors 5 cm and larger. Int J Radiat Oncol Biol Phys 66:358–364. https://doi.org/10.1016/j.ijrobp.2006.05.001 CrossRefPubMed

17.

Johnson ME, Handorf EA, Martin JM, Hayes SB (2014) Postmastectomy radiation therapy for T3N0: A SEER analysis. Cancer 120:3569–3574. https://doi.org/10.1002/cncr.28865 CrossRefPubMedPubMedCentral

18.

Taghian AG, Jeong J‑H, Mamounas EP et al (2006) Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol 24:3927–3932. https://doi.org/10.1200/JCO.2006.06.9054 CrossRefPubMed

19.

Fowble BL, Einck JP, Kim DN et al (2012) Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II–III breast cancer. Int J Radiat Oncol Biol Phys 83:494–503. https://doi.org/10.1016/j.ijrobp.2012.01.068 CrossRefPubMed

20.

White J, Mamounas E (2014) Locoregional radiotherapy in patients with breast cancer responding to neoadjuvant chemotherapy: a paradigm for treatment individualization. J Clin Oncol 32:494–495. https://doi.org/10.1200/JCO.2013.53.4974 CrossRefPubMed

21.

Rusthoven CG, Rabinovitch RA, Jones BL et al (2016) The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis. Ann Oncol 27:818–827. https://doi.org/10.1093/annonc/mdw046 CrossRefPubMed

22.

Daveau C, Stevens D, Brain E et al (2010) Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy? Int J Radiat Oncol Biol Phys 78:337–342. https://doi.org/10.1016/j.ijrobp.2009.08.053 CrossRefPubMed

23.

Bae SH, Park W, Huh SJ et al (2012) Radiation treatment in pathologic N0-N1 patients treated with neoadjuvant chemotherapy followed by surgery for locally advanced breast cancer. J Breast Cancer 15:329–328. https://doi.org/10.4048/jbc.2012.15.3.329 CrossRefPubMedPubMedCentral

24.

Noh JM, Park W, Suh C‑O et al (2014) Is elective nodal irradiation beneficial in patients with pathologically negative lymph nodes after neoadjuvant chemotherapy and breast-conserving surgery for clinical stage II–III breast cancer? A multicentre retrospective study (KROG 12-05). Br J Cancer 110:1420–1426. https://doi.org/10.1038/bjc.2014.26 CrossRefPubMedPubMedCentral

25.

Kim KH, Noh JM, Kim YB et al (2015) Does internal mammary node irradiation affect treatment outcome in clinical stage II–III breast cancer patients receiving neoadjuvant chemotherapy? Breast Cancer Res Treat 152:589–599. https://doi.org/10.1007/s10549-015-3505-1 CrossRefPubMed

26.

McGuire SE, Gonzalez-Angulo AM, Huang EH et al (2007) Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 68:1004–1009. https://doi.org/10.1016/j.ijrobp.2007.01.023 CrossRefPubMedPubMedCentral

27.

Nagar H, Mittendorf EA, Strom EA et al (2011) Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer. Int J Radiat Oncol Biol Phys 81:782–787. https://doi.org/10.1016/j.ijrobp.2010.06.027 CrossRefPubMed

28.

Le Scodan R, Selz J, Stevens D et al (2012) Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys 82:e1–e7. https://doi.org/10.1016/j.ijrobp.2010.12.054 CrossRefPubMed

29.

Shim SJ, Park W, Huh SJ et al (2014) The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II–III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05). Int J Radiat Oncol Biol Phys 88:65–72. https://doi.org/10.1016/j.ijrobp.2013.09.021 CrossRefPubMed

30.

Xin F, Yu Y, Yang Z‑J et al (2016) Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy. Tumor Biol 37:1–10. https://doi.org/10.1007/s13277-015-4640-3 CrossRef

31.

Meattini I, Cecchini S, Di Cataldo V et al (2014) Postmastectomy radiotherapy for locally advanced breast cancer receiving neoadjuvant chemotherapy. Biomed Res Int 2014:1–12. https://doi.org/10.1155/2014/719175 CrossRef

32.

Liu J, Mao K, Jiang S et al (2016) The role of postmastectomy radiotherapy in clinically node-positive, stage II–III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB. Oncotarget 7:24848–24859. https://doi.org/10.18632/oncotarget.6664 PubMedCrossRef

33.

Kantor O, Pesce C, Singh P et al (2017) Post-mastectomy radiation therapy and overall survival after neoadjuvant chemotherapy. J Surg Oncol 28:2396–2399. https://doi.org/10.1002/jso.24551 CrossRef

34.

Mamounas EP, Cortazar P, Zhang L et al (2014) Locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC): pooled-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). J Clin Oncol 32:61–61. https://doi.org/10.1200/jco.2014.32.26_suppl.61 CrossRef

35.

Marks LB, Prosnitz LR (2014) Reducing local therapy in patients responding to preoperative systemic therapy: are we outsmarting ourselves? J Clin Oncol 32:491–493. https://doi.org/10.1200/JCO.2013.51.3523 CrossRefPubMed

36.

Poortmans PMP, Arenas M, Livi L (2017) Over-irradiation. Breast 31:295–302. https://doi.org/10.1016/j.breast.2016.07.022 CrossRefPubMed

37.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 19:27–39. https://doi.org/10.1016/S1470-2045(17)30777-5 CrossRef

38.

Mieog JSD, van der Hage JA, van de Velde CJH (2007) Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 94:1189–1200. https://doi.org/10.1002/bjs.5894 CrossRefPubMed

39.

Mauri D, Pavlidis N, Ioannidis JPA (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97:188–194. https://doi.org/10.1093/jnci/dji021 CrossRefPubMed

40.

Budach W, Bölke E, Kammers K et al (2015) Adjuvant radiation therapy of regional lymph nodes in breast cancer—a meta-analysis of randomized trials—an update. Radiat Oncol 10:1–7. https://doi.org/10.1186/s13014-015-0568-4 CrossRef

41.

McGale P, Cutter D, Darby SC et al (2016) Can observational data replace randomized trials? J Clin Oncol 34:3355–3357. https://doi.org/10.1200/JCO.2016.68.8879 CrossRefPubMed

42.

Gianni L, Pienkowski T, Im Y‑H et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25–32. https://doi.org/10.1016/S1470-2045(11)70336-9 CrossRefPubMed

43.

Schneeweiss A, Chia S, Hickish T et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24:2278–2284. https://doi.org/10.1093/annonc/mdt182 CrossRefPubMed

44.

Dawood S, Merajver SD, Viens P et al (2011) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22:515–523. https://doi.org/10.1093/annonc/mdq345 CrossRefPubMed

45.

Rea D, Francis A, Hanby AM et al (2015) Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. Br J Cancer 112:1613–1615. https://doi.org/10.1038/bjc.2015.115 CrossRefPubMedPubMedCentral

46.

Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med 6:e1000097. https://doi.org/10.1371/journal.pmed.1000097 CrossRefPubMedPubMedCentral

Title: Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer
A systematic review
Authors: David Krug
René Baumann
Wilfried Budach
Jürgen Dunst
Petra Feyer
Rainer Fietkau
Wulf Haase
Wolfgang Harms
Thomas Hehr
Marc D. Piroth
Felix Sedlmayer
Rainer Souchon
Frederik Wenz
Rolf Sauer
Publication date: 01-07-2018
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 7/2018
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1270-x

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer

A systematic review

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2018

Kein Nachweis einer reduzierten Spättoxizität durch Dosisreduktion im elektiven Lymphknotenbereich in der primären Radiochemotherapie von Kopf-Hals-Tumoren

Systemic administration of heparin ameliorates radiation-induced oral mucositis—preclinical studies in mice

Shorter treatment times reduce the impact of intra-fractional motion

Verlängerung des rezidivfreien und Gesamtüberlebens beim Ovarialkarzinom im Stadium III durch hypertherme intraperitoneale Chemotherapie (HIPEC)

Cancer patients’ wish for psychological support during outpatient radiation therapy

Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy